Real-world experience with abiraterone
Mené sur 2 314 patients atteints d'un cancer métastatique de la prostate résistant à la castration et ayant progressé après une chimiothérapie, cet essai international de phase III évalue la toxicité et l'efficacité de l'acétate d'abiratérone (durée médiane de suivi : 5,7 mois)
In The Lancet Oncology, Cora Sternberg and colleagues present results of an early-access protocol trial of abiraterone acetate for treatment of patients with metastatic castration-resistant prostate cancer who had progressed after taxane chemotherapy and possibly one additional regimen. They provide real-world data for abiraterone in a broad global population, including countries that were not part of the initial registration trial that led to regulatory approval for abiraterone (COU-AA-301). In ...
The Lancet Oncology , commentaire, 2013